PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7766770

Asymptotic confidence bands for generalized nonlinear regression models.

C Cox·G Ma
View original source ↗Export metadata ↓

Abstract

Asymptotic confidence bands for generalized nonlinear regression models are developed. These are based on a combination of the S method of Scheffe, together with the delta method which is used to approximate the mean function by a linear combination of the parameters. The approach can be used in any situation where large sample theory can be applied to yield asymptotically normal estimates of the parameters, together with a consistent estimate of the large sample covariance matrix. Alternative formulations for various special cases allow the use of restricted range bands. A number of examples are given, including a pharmacokinetic model, a logit model with a background response rate, and a parametric survival model.

Explore related subjects

Administration, InhalationAnimalsBiometryConfidence IntervalsHumansMathematicsMiceModels, StatisticalPharmaceutical PreparationsPharmacokineticsRegression AnalysisSoftwareJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C Cox, G Ma. 1995. Asymptotic confidence bands for generalized nonlinear regression models.. https://pubmed.ncbi.nlm.nih.gov/7766770/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2008

Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas.

In an attempt to improve local control, we assessed the feasibility of the addition of 4 min of carbogen inhalation (as a radiosensitizer) to daily fractionated radiotherapy in pediatric patients with high grade and/or diffuse brainstem gliomas. Ten patients inhaled carbogen for >90% of the radiation treatments. Median survival time from start of therapy was 0.80 years. Carbogen inhalation did not appear to improve the dismal prognosis.

Administration, Inhalation↗
PubMed2007

2. Advances in pharmacotherapy for COPD.

Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease in the world. In 1999, COPD ranked sixth among the most common causes of death and twelfth as a worldwide burden of disease. It has been estimated that by the year 2020 COPD will be the third leading cause of death and fifth as a worldwide burden of disease. Thus, COPD is a major medical problem and there is evidence that it is increasing throughout the world. Despite recognition of COPD as an important international health problem, COPD has been neglected among common diseases, with little investment in research on its underlying cellular and molecular mechanisms. Recently, global and Japanese guidelines for COPD have been published. These guidelines seem to be useful to improve the underdiagnosis and undertreatment of COPD. In this review, I describe briefly the current recommendation for pharmacological therapy of stable COPD according to the global and Japanese guidelines for COPD.

Administration, Inhalation↗